Lipid abnormalities in renal disease

Journal of the Royal Society of Medicine

Volumn 93, Issue 4, 2000, Pages 178-182

  Majumdar, Arghya ^a   Wheeler, David C ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PREDNISOLONE; STATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIET THERAPY; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MYOSITIS; PROTEINURIA; REVIEW; RHABDOMYOLYSIS;

EID: 0033999175     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1177/014107680009300406     Document Type: Review

References (38)

1. 1 Virchow R. A more precise account of fatty metamorphosis. In: Virchow R, ed. Cellular Pathology. 2nd edition. London: Churchill, 1960:342-66
2. 2 Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: Causes, consequences and treatment. Am J Kidney Dis 1994; 23:331-46
3. 3 Attman P-O, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993;21:573-92
4. 4 Wheeler DC. Should hyperlipidaemia in dialysis patients be treated? Nephrol Dial Transplant 1997;12:19-21
5. 5 Dimény E, Fellström B. Metabolic abnormalities in renal transplant recipients. Risk factors and predictors of chronic graft dysfunction? Nephrol Dial Transplant 1997;12:21-24
6. 6 Wheeler DC. Lipids - What is the evidence for their role in progressive renal disease? Nephrol Dial Transplant 1995;10:14-16
7. 7 Deckelbaum RJ. Structure and composition of human plasma lipoproteins. In: Olsson AG, ed. Atherosclerosis: Biology and Clinical Science. Edinburgh: Churchill Livingstone, 1987:251-55
8. 8 Mahley RW, Innerarity TL, Rall SC, et al. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 1984;25:1277-94
9. 9 Steyrer E, Durovic S, Frank S, et al. The role of lecithin:cholesterol acyltransferase for lipoprotein(a) assembly. Structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma. J Clin Invest 1994;94:2330-40
10. 10 Schanu AM, Fless GM. Lipoprotein(a). Heterogeneity and biological relevance. J Clin Invest 1990;85:1709-15
11. 11 Newmark SR, Anderson CF, Donadio JV, et al. Lipoprotein profiles in adult nephrotics. Mayo Clin Proc 1975;50:359-64
12. 12 Joven J, Villabona C, Vilella E, et al. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 1990;323:579-84
13. 13 Appel G. Lipid abnormalities in renal disease. Kidney Int 1991;39:169-83
14. 14 Yamauchi A, Fukuhara Y, Yamamoto S, et al. Oncotic pressure regulates gene transcriptions of albumin and apolipoprotein B in cultured rat hepatoma cells. Am J Physiol 1992;263:C397-404
15. 15 Warwick GL, Packard CJ, Demant T, et al. Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria. Kidney Int 1991;40:129-38
16. 16 Vega G, Toto RD, Grundy SM. Metabolism of low density lipoproteins in nephrotic dyslipidemia: comparison of hypercholesterolemia alone and combined hyperlipidemia. Kidney Int 1995;47:579-86
17. 17 Davies RW, Staprans I, Hutchison FN, et al. Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest 1990;86:600-5
18. 18 Rajman I, Harper L, McPake D, et al. Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant 1998;13:2281-7
19. 19 Gruber KK, Haffner SM, Tuttle KR. Increased Lp(a) concentrations in chronic renal failure [Abstract]. J Am Soc Nephrol 1992;3:333
20. 20 Brown WV, Baginsky ML. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun 1972;46:375-82
21. 21 Cheung AK, Parker CJ, Ren K, et al. Increased lipase inhibition in uremia; Identification of pre-β HDL as a major inhibitor in normal and uremic plasma. Kidney Int 1996;49:1360-71
22. 22 Wheeler DC. Abnormalities of lipoprotein metabolism in CAPD patients. Kidney Int 1996;50(suppl. 56):S41-6
23. 23 Avram MM, Goldswasser P, Burrell DE, et al. The uremic dyslipidemia: a cross-sectional and longitudinal study. Am J Kidney Dis 1992;20:324-35
24. 24 Blankestijn PJ, Vos PF, Rabelink TJ, et al. High-flux dialysis membranes improve lipid profile in chronic haemodialysis patients. J Am Soc Nephrol 1995;5:1703-8
25. 25 Dimény E, Wahlberg J, Lithell H, et al. Hyperlipidaemia in renal transplantation-risk factor for long term graft outcome. Eur J Clin Invest 1995;25:574-83
26. 26 Attman P-O, Alaupovic P, Gustafson A. Serum apolipoprotein profile of patients with chronic renal failure. Kidney Int 1987;32:368-75
27. 27 Cressman MD, Heyka RJ, Paganini EP, et al. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992;86:475-82
28. 28 Keane WF, Kasiske BL, O'Donnell MP, et al. The role of altered lipid metabolism in the progression of renal disease: experimental evidence. Am J Kidney Dis 1991;17:38-42
29. 29 Moorhead JF, Wheeler DC, Varghese Z. Glomerular structures and lipids in progressive renal disease. Am J Med 1989;87(suppl 5N):12N-20N
30. 30 Neugarten J, Schlondorff D. Lipoprotein interactions with glomerular cells and matrix. Contemp Issues Nephrol 1991;24:173-206
31. 31 Isoniemi H, Nurminen M, Tikkanen MJ, et al. Risk factors predicting chronic rejection of renal allografts. Transplantation 1994; 57:68-72
32. 32 Fellström BC, Larsson E. Pathogenesis and treatment perspectives of chronic graft rejection (CVR). Immunol Rev 1993;134: 83-98.
33. 33 Sanfelippo ML, Swenson RS, Reaven GM. Reduction of plasma triglylcerides by diet in subjects with chronic renal failure. Kidney Int 1977;11:54-61
34. 34 Massy ZA, Ma JZ, Louis TA, Kasiske BL. Lipid-lowering therapy in patients with renal disease. Kidney Int 1995;48:188-98
35. 35 Wheeler DC. Statins and the kidney. Curr Opin Nephrol Hypertens 1998;7:579-84
36. 36 Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996;348:1079-82
37. 37 O'Donnell MP, Kasiske BL, Kim Y, et al. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993;91:83-7
38. 38 Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation. A pilot study. Transplantation 1996;61:1469-74